{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:06:49Z","timestamp":1773515209123,"version":"3.50.1"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background\/Objectives: Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease resulting in proximal muscle weakness and paralysis. SMA treatment has radically changed in the past 10 years thanks to the development of novel therapies such as nusinersen and onasemnogene abeparvovec. Since the advent of new treatments, the incidence and perioperative risk factors of patients with SMA undergoing longer, higher-risk surgeries are unknown. We hypothesized that patients with SMA would be at an overall elevated risk for postoperative pulmonary complications (PPC) and prolonged length of stay compared to the general population, but that this would be reduced in patients undergoing surgery in the years after the release of new therapies. Methods: Patients who underwent surgery at a continuously enrolled American College of Surgeons National Surgery Quality Improvement Program-Pediatric hospital from 1 January 2012, to 31 December 2021, were included in this study. Cases with missing covariate or primary outcome data were excluded from the analysis. Patients with ages greater than 17 years, preoperative tracheostomy, preoperative mechanical ventilation, missing covariate or primary outcome data were excluded. Patients with SMA were identified by their ICD-9 and 10 codes. A cutoff year of 2018 was chosen for analysis of the primary outcomes as this was a full year after nusinersen received FDA approval. Results: On univariable analysis, the risk for PPC in patients with SMA was reduced in patients undergoing surgery in 2018 or later compared to pre-2018 (pre-2018 OR 4.44, 95% CI 1.56\u20139.6, p = 0.008; post-2018 OR 3.48, 95% CI 0.84\u20139.12, p = 0.08). On multivariable analysis, the association between SMA and PPC substantially decreased in 2018 and after but was no longer statistically significant (pre-2018 OR 1.96, 95% CI 0.80\u20134.80, p = 0.14; post-2018 OR 1.03, 95% CI 0.33\u20133.26, p = 0.96). SMA was positively associated with LOS in the pre-2018 cohort, with a coefficient from a log linear model of 0.67 (95% CI 0.32\u20131.01; p &lt; 0.001), and SMA adding an additional 1.93 days in LOS. For data post-2018, the effect of SMA on LOS was no longer statistically significant. Conclusions: Utilizing a large dataset, we found a reduced association between SMA and PPC a year following widespread implementation of SMN antisense oligonucleotide therapy, and a statistically significant reduction in LOS in patients with SMA after 2018. This may reflect improved motor outcomes and respiratory mechanics in the new treatment era.<\/jats:p>","DOI":"10.3390\/children12091255","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:32:32Z","timestamp":1758187952000},"page":"1255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduction in Perioperative Risk in Patients with Spinal Muscular Atrophy Following the Release of Disease-Modifying Therapies: An Analysis of the National Surgical Quality Improvement Program Database"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-0236","authenticated-orcid":false,"given":"Erin","family":"Toaz","sequence":"first","affiliation":[{"name":"Department of Pediatric Anesthesiology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6987-9248","authenticated-orcid":false,"given":"Nisha","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Pediatric Anesthesiology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-7967","authenticated-orcid":false,"given":"Keith","family":"Kilner","sequence":"additional","affiliation":[{"name":"Department of Pediatric Anesthesiology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Cheon","sequence":"additional","affiliation":[{"name":"Department of Pediatric Anesthesiology, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago, Northwestern University, Chicago, IL 60611, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"Mercuri","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in Treatment of Spinal Muscular Atrophy\u2014New Phenotypes, New Challenges, New Implications for Care","volume":"7","author":"Schorling","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1460-9592.2009.03055.x","article-title":"Anesthesia and perioperative medical management of children with spinal muscular atrophy","volume":"19","author":"Graham","year":"2009","journal-title":"Pediatr. Anesth."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/pan.12909","article-title":"Anesthetic management of 877 pediatric patients undergoing muscle biopsy for neuromuscular disorders: A 20\u2014Year review","volume":"26","author":"Shapiro","year":"2016","journal-title":"Pediatr. Anesth."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience","volume":"31","author":"Hache","year":"2016","journal-title":"J. Child. Neurol."},{"key":"ref_6","first-page":"A02200100","article-title":"Nusinersen treatment of spinal muscular atrophy\u2014A systematic review","volume":"67","author":"Albrechtsen","year":"2020","journal-title":"Dan. Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Day, J.W., Howell, K., Place, A., Long, K., Rossello, J., Kertesz, N., and Nomikos, G. (2022). Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr., 22.","DOI":"10.1186\/s12887-022-03671-x"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"Darryl","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/pan.13500","article-title":"A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen","volume":"28","author":"Bielsky","year":"2018","journal-title":"Pediatr. Anesth."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/pan.13964","article-title":"Anesthetic management of pediatric patients undergoing intrathecal nusinersen administration for treatment of spinal muscular atrophy: A single\u2014Center experience","volume":"31","author":"Brollier","year":"2021","journal-title":"Pediatr. Anesth."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/bcp.15718","article-title":"Procedural sedation for paediatric patients with spinal muscular atrophy undergoing intrathecal treatment","volume":"89","author":"Sever","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_14","unstructured":"American College of Surgeons National Surgical Quality Improvement Program\u2014Pediatri (2014). User Guide for the 2013 ACS NSQIP Pediatric Participant Use Data File (PUF), American College of Surgeons."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1301082","article-title":"A trial of intraoperative low-tidal-volume ventilation in abdominal surgery","volume":"369","author":"Futier","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.sla.0000183348.15117.ab","article-title":"Preoperative risk factors and surgical complexity are more predictive of costs than postoperative complications: A case study using the National Surgical Quality Improvement Program (NSQIP) database","volume":"242","author":"Davenport","year":"2005","journal-title":"Ann. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","article-title":"Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy","volume":"22","author":"Kay","year":"2020","journal-title":"Genet. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.nmd.2021.03.012","article-title":"Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen","volume":"31","author":"Coratti","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4103\/ija.IJA_312_20","article-title":"Peri-operative management of children with spinal muscular atrophy","volume":"64","author":"Hanna","year":"2020","journal-title":"Indian J. Anaesth."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.36469\/63185","article-title":"Healthcare Utilization, Costs of Care, and Mortality Among Psatients With Spinal Muscular Atrophy","volume":"6","author":"Tan","year":"2019","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","article-title":"Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases","volume":"19","author":"Holm","year":"2022","journal-title":"RNA Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1002\/jcph.2134","article-title":"Natural History and Real\u2014World Data in Rare Diseases: Applications, Limitations, and Future Perspectives","volume":"62","author":"Liu","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"m3731","DOI":"10.1136\/bmj.m3731","article-title":"Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: National derivation and validation cohort study","volume":"371","author":"Clift","year":"2020","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/jamia\/ocac062","article-title":"Development and validation of predictive models for COVID-19 outcomes in a safety-net hospital population","volume":"29","author":"Hao","year":"2022","journal-title":"J. Am. Med. Inform. Assoc."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/9\/1255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:41Z","timestamp":1760035661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/9\/1255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["children12091255"],"URL":"https:\/\/doi.org\/10.3390\/children12091255","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}